Summary: This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011].
These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service.
OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
* Delivery time in business days.Occasional delay may occur due to complexity of the constructs.
All shRNA Citations:
Mitochondrial damage and cholesterol storage in human hepatocellular carcinoma cells with silencing of UBIAD1 gene expression, Morales, CR;Grigoryeva, LS;Pan, X;Bruno, L;,
Molecular Genetics and Metabolism Reports Sep 2014
[UBIAD1] Transmembrane Domain Targeting Peptide Antagonizing ErbB2/Neu Inhibits Breast Tumor Growth and Metastasis, Arpel, A;Sawma, P;Spenlé, C;Fritz, J;Meyer, L;Garnier, N;Velázquez-Quesada, I;Hussenet, T;Aci-Sèche, S;Baumlin, N;Genest, M;Brasse, D;Hubert, P;Crémel, G;Orend, G;Laquerrière, P;Bagnard, D;,
Cell Rep Sep 2014
[ERBB2] PGC-1a mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis, LeBleu, VS;O'Connell, JT;Gonzalez Herrera, KN;Wikman, H;Pantel, K;Haigis, MC;de Carvalho, FM;Damascena, A;Domingos Chinen, LT;Rocha, RM;Asara, JM;Kalluri, R;,
Nat. Cell Biol. Sep 2014
[PPARGC1A] Leukocyte specific protein-1: A novel regulator of hepatocellular proliferation and migration deleted in human HCC, Koral, K;Paranjpe, S;Bowen, WC;Mars, W;Luo, J;Michalopoulos, GK;,
Hepatology Sep 2014
[ LSP1] Inhibition of tumor-associated avß3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo, Contois, LW;Akalu, A;Caron, JM;Tweedie, E;Cretu, A;Henderson, T;Liaw, L;Friesel, R;Vary, C;Brooks, PC;,
Angiogenesis Sep 2014
[ITG?3] Pannexin 1 and Pannexin 3 Channels Regulate Skeletal Muscle Myoblast Proliferation and Differentiation, Langlois, S;Xiang, X;Young, K;Cowan, BJ;Penuela, S;Cowan, KN;,
J. Biol. Chem. Sep 2014
[Panx3] TGF-ß1 mediates the radiation response of prostate cancer, Wu, CT;Hsieh, CC;Yen, TC;Chen, WC;Chen, MF;,
J. Mol. Med. Sep 2014
[TGFB1] Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells, Tripathi, R;Ash, D;Shaha, C;,
J. Cell. Mol. Med. Sep 2014
[ATG5] Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells, Tripathi, R;Ash, D;Shaha, C;,
J. Cell. Mol. Med. Sep 2014
[BECN1] Bile Acids Regulate Nuclear Receptor (Nur77) Expression and Intracellular Location to Control Proliferation and Apoptosis, Hu, Y;Chau, T;Liu, HX;Liao, D;Keane, R;Nie, Y;Yang, H;Wan, YJ;,
Mol. Cancer Res. Sep 2014
* Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping